Monoclonal antibodies targeting IL-33, currently in clinical trials for other inflammatory lung diseases, could potentially be repurposed for PAH, offering a more selective approach that may circumvent the broader and context-dependent action of BMP9-based therapies. Here, GDF2 is linked to pulmonary arterial hypertension.